| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8888745 | ORGANON | Applicator for inserting an implant |
Aug, 2026
(2 years from now) | |
| US10821277 | ORGANON | Kit for and method of assembling an applicator for inserting an implant |
May, 2027
(3 years from now) | |
| US8722037 | ORGANON | X-ray visible drug delivery device |
Sep, 2027
(3 years from now) | |
| US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(6 years from now) | |
Implanon is owned by Organon.
Implanon contains Etonogestrel.
Implanon has a total of 4 drug patents out of which 0 drug patents have expired.
Implanon was authorised for market use on 17 July, 2006.
Implanon is available in implant;implantation dosage forms.
Implanon can be used as prevention of pregnancy.
The generics of Implanon are possible to be released after 28 July, 2030.
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
IMPLANON family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic